What is Causaly?
Founded in 2018, Causaly operates at the intersection of artificial intelligence and biomedical research. The company provides a sophisticated AI platform designed to transform how life science organizations navigate vast amounts of scientific literature and experimental data. By automating the extraction of causal relationships from complex datasets, Causaly enables researchers to make faster, more informed decisions in drug discovery and development. Its technology serves as a critical infrastructure layer for modern research teams, effectively reducing the time and cost associated with identifying novel therapeutic targets and validating research hypotheses.
How much funding has Causaly raised?
Causaly has raised a total of $81.8M across 3 funding rounds:
Series A
$4.8M
Unspecified
$17M
Series B
$60M
Series A (2019): $4.8M with participation from Marathon Venture Capital, Pentech Ventures, and Ebrd Vcip
Unspecified (2021): $17M led by Index Ventures, Pentech, Marathon, and EBRD
Series B (2023): $60M supported by Marathon Venture Capital, Pentech, ICONIQ Growth, and Index Ventures
Key Investors in Causaly
ICONIQ Growth
ICONIQ Growth partners with visionary entrepreneurs to drive global impact, leveraging a unique ecosystem of business leaders to support companies from early growth stages to IPO.
Marathon Venture Capital
A seed-stage fund dedicated to assisting ambitious European founders in building world-class technology companies, with a specific focus on AI and biopharma innovation.
Index Ventures
A prominent venture firm investing in the next generation of entrepreneurs from seed to IPO, known for backing category-defining companies across the globe.
What's next for Causaly?
With the successful closure of its latest funding round, Causaly is well-positioned to scale its enterprise operations and deepen its technological moat. The company is expected to focus on expanding its AI capabilities to handle increasingly complex biological datasets, further integrating its platform into the workflows of global pharmaceutical giants. Strategic priorities likely include the recruitment of top-tier engineering talent, the enhancement of its natural language processing engines, and the pursuit of broader commercial partnerships. As the life sciences industry continues to embrace digital transformation, Causaly's ability to provide actionable insights from unstructured data will remain a key driver of its long-term growth trajectory and competitive advantage.
See full Causaly company page
